Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CF102 versus placebo in second-line advanced hepatocellular carcinoma with Child-Pugh class B cirrhosis
2014-000489-23Phase 2Completed
- Sponsor
- Can-Fite BioPharma Ltd.
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing CF102 with Placebo (2 arms). Primary endpoint: Overall survival. Started Oct 2014; status: completed.
02
Drugs
namodenoson
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2014-000489-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000489-23.